These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9712485)

  • 1. The cytokine modulation of acute graft-versus-host disease.
    Ferrara JL
    Bone Marrow Transplant; 1998 Jun; 21 Suppl 3():S13-5. PubMed ID: 9712485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of cytokines in acute graft-versus-host disease.
    Hill GR; Krenger W; Ferrara JL
    Cytokines Cell Mol Ther; 1997 Dec; 3(4):257-66. PubMed ID: 9740354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of cytokines in graft-versus-host reactions and disease.
    Jadus MR; Wepsic HT
    Bone Marrow Transplant; 1992 Jul; 10(1):1-14. PubMed ID: 1515873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological advances in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Duran-Struuck R; Reddy P
    Transplantation; 2008 Feb; 85(3):303-8. PubMed ID: 18301323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
    Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
    Tian Y; Deng YB; Huang YJ; Wang Y
    Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease.
    Cooke KR; Olkiewicz K; Erickson N; Ferrara JL
    J Endotoxin Res; 2002; 8(6):441-8. PubMed ID: 12697087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulation of inflammatory cytokines in unrelated bone marrow transplantation.
    Nagler A; Bishara A; Brautbar C; Barak V
    Cytokines Cell Mol Ther; 1998 Sep; 4(3):161-7. PubMed ID: 9825841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
    Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.
    Jung U; Foley JE; Erdmann AA; Toda Y; Borenstein T; Mariotti J; Fowler DH
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):905-18. PubMed ID: 16920556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology of acute graft-versus-host disease.
    Reddy P
    Hematol Oncol; 2003 Dec; 21(4):149-61. PubMed ID: 14735553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of extracorporeal photopheresis on intracellular cytokine expression in chronic cutaneous graft-versus-host disease.
    Darvay A; Salooja N; Russell-Jones R
    J Eur Acad Dermatol Venereol; 2004 May; 18(3):279-84. PubMed ID: 15096136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of graft-versus-host disease: role of regulatory T lymphocytes.
    Hess AD
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):13-21. PubMed ID: 16399597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pathophysiology of acute graft-versus-host disease.
    Jaksch M; Mattsson J
    Scand J Immunol; 2005 May; 61(5):398-409. PubMed ID: 15882431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alloreactive CD4 T lymphocytes responsible for acute and chronic graft-versus-host disease are contained within the CD45RChigh but not the CD45RClow subset.
    Xystrakis E; Bernard I; Dejean AS; Alsaati T; Druet P; Saoudi A
    Eur J Immunol; 2004 Feb; 34(2):408-17. PubMed ID: 14768045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.